However, current next-generation clinical sequencing methods of peripheral blood do not routinely cover the entire RB1 locus, and even with genome sequencing of peripheral blood and tumor samples targeting RB1 (23), identification of epigenetic changes and chromosomal phase information requires secondary analysis, limiting their ability to provide parent-of-origin diagnostics. This evidence concerns the gene RB1 and neoplasm.